ATB 227
Alternative Names: ATB-227Latest Information Update: 09 May 2023
At a glance
- Originator AltiBio
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 27 Apr 2023 Preclinical trials in Unspecified in USA (unspecified route) (AltiBio pipeline, April 2023)